Login / Signup

Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy.

Jack A TerrettHuifen ChenDaniel G ShoreElisia VillemureRobin Larouche-GauthierMartin DéryFrancis BeaumierLéa Constantineau-ForgetChantal Grand-MaîtreLuce LépissierStéphane CiblatClaudio SturinoYong ChenBaihua HuAijun LuYunli WangAndrew P CridlandStuart I WardDavid H HackosRebecca M ReeseShannon D ShieldsJun ChenAlessia BalestriniLorena Riol-BlancoWyne P LeeJohn LiuEric SutoXiumin WuJuan ZhangJustin Q LyHank LaKevin M JohnsonMatt BaumgardnerKang-Jye ChouAlexis RohouLionel RougéBrian S SafinaSteven MagnusonMatthew Volgraf
Published in: Journal of medicinal chemistry (2021)
Transient receptor potential ankyrin 1 (TRPA1) is a nonselective calcium-permeable ion channel highly expressed in the primary sensory neurons functioning as a polymodal sensor for exogenous and endogenous stimuli and has generated widespread interest as a target for inhibition due to its implication in neuropathic pain and respiratory disease. Herein, we describe the optimization of a series of potent, selective, and orally bioavailable TRPA1 small molecule antagonists, leading to the discovery of a novel tetrahydrofuran-based linker. Given the balance of physicochemical properties and strong in vivo target engagement in a rat AITC-induced pain assay, compound 20 was progressed into a guinea pig ovalbumin asthma model where it exhibited significant dose-dependent reduction of inflammatory response. Furthermore, the structure of the TRPA1 channel bound to compound 21 was determined via cryogenic electron microscopy to a resolution of 3 Å, revealing the binding site and mechanism of action for this class of antagonists.
Keyphrases